Tsuguo Iwatani

9PUBLICATIONS
35CO-AUTHORS
Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCross-sectional analysisDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 08, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

|Jun 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

|Jul 29, 2025
Definitions of, Advances in, and Treatment Strategies for Breast Cancer Oligometastasis.

Tadahiko Shien, Shogo Nakamoto, Yuki Fujiwara

|Jan 09, 2025
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Toshinari Yamashita, Shigehira Saji, Toshimi Takano

|Oct 18, 2023
Prospective analysis of patient-reported outcomes and physician-reported outcomes with gynecologic cancer chemotherapy.

Tomo Takenaga, Shiho Kuji, Ken-Ichiro Tanabe

|Jul 03, 2023
Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.

Sumito Saeki, Tsuguo Iwatani, Atsuko Kitano

Pageof 2

Frequent Collaborators

4 joint publications

Yasuaki Sagara

3 joint publications

Norikazu Masuda

3 joint publications

Satoshi Morita

3 joint publications

Shigehira Saji